ViroStatics claimed that AV-HALTS are a new class of drugs that combine direct anti-viral activity with a reduction in the chronically elevated immune system activation that is now known to play a major role in the progression of HIV disease, ultimately leading to AIDS. ViroStatics has brought AV-HALT, VS411, into Phase II development.
Franco Lori, president and CEO of ViroStatics, said: “Our new partnership brings together both companies’ substantial intellectual properties and significant libraries of Kinase Inhibitors.”
Gyorgy Keri, CEO of Vichem Chemie, said: “The expertise of ViroStatics in translating basic discoveries into clinical applications -from the bench to the bed side – is well appreciated. The Companies’ strengths are both complimentary and synergistic.
“We look forward to a successful partnership to identify new and exciting compounds that ViroStatics will develop into important new therapies against HIV/AIDS and other chronic diseases.”